Appendix 1
List of applicable laws, regulations and administrative provisions
For the European Community:
Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products, as extended, widened and amended.
Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products, as extended, widened and amended.
Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products, as widened and amended.
Council Directive 91/356/EEC of 13 June 1991 laying down the principles and guidelines of good manufacturing practice for medicinal products for human use.
Commission Directive 91/412/EEC of 23 July 1991 laying down the principles and guidelines of good manufacturing practice for veterinary medicinal products.
Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products.
Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use.
Guide to Good Distribution Practice (94/C 63/03).
Current version of the Guide to Good Manufacturing Practice, Rules Governing Medicinal Products in the European Community, Volume IV.
For the United States:
Relevant sections of the United States Federal Food, Drug, and Cosmetic Act and the United States Public Health Service Act.
Relevant sections of Title 21, United States Code of Federal Regulations (CFR) Parts 1-99, Parts 200-299, Parts 500-599, and Parts 600-799.
Relevant sections of the FDA Investigations Operations Manual, the FDA Regulatory Procedures Manual, the FDA Compliance Policy Guidance Manual, the FDA Compliance Program Guidance Manual, and other FDA guidances.
Appendix 2
List of Authorities
UNITED STATES:
In the United States, the regulatory authority is the Food and Drug Administration.
EUROPEAN COMMUNITY:
In the European Community, the regulatory authorities are the following:
BELGIUM |
Inspection générale de la Pharmacie
Algemene Farmaceutische Inspectie
DENMARK | Lægemiddelstyrelsen
GERMANY | Bundesministerium für Gesundheit
GREECE |
Εθνιϰóς Oϱγανισμός Φαϱμάϰου
Ministry of Health and Welfare
National Drug Organization (E.O.F)
SPAIN |
for medicinal products for human use:
Ministerio de Sanidad y Consumo
Subdirección General de Control Farmacéutico
for medicinal products for veterinary use:
Ministerio de Agricultura, Pesca y Alimentación (MAPA)
Dirección General de la Producción Agraria
FRANCE |
for medicinal products for human use:
Agence du Médicament
for veterinary medicinal products:
Agence Nationale du Médicament Vétérinaire
IRELAND | Irish Medicines Board
ITALY |
for medicinal products for human use:
Ministero della Sanità
Dipartimento Farmaci e Farmacovigilanza
for medicinal products for veterinary use:
Ministero della Sanità
Dipartimento alimenti e nutrizione e sanità pubblica veterinaria — Div. IX
LUXEMBOURG | Division de la Pharmacie et des Médicaments
NETHERLANDS | Staat der Nederlanden
AUSTRIA | Bundesministerium für Arbeit, Gesundheit und Soziales
PORTUGAL |
for human and veterinary (non-immunologicals):
Instituto da Farmácia e do Medicamento — INFARMED
for veterinary immunologicals:
Direcção — Geral de Veterinaria
FINLAND |
LääkelaitosLäkemedelsverket
(National Agency for Medicines)
SWEDEN | Läkemedelsverket — Medical Products Agency
UNITED KINGDOM |
for human and veterinary (non-immunologicals):
Medicines Control Agency
for veterinary immunologicals:
Veterinary Medicines Directorate
EUROPEAN COMMUNITY |
Commission of the European Communities
European Agency for the Evaluation of Medicinal Products (EMEA)
Appendix 3
Indicative list of Products covered by the Sectoral Annex
Recognising that precise definitions of medicinal products and drugs are to be found in the legislation referred to above, an indicative list of products covered by the agreement is given below:
human medicinal products including prescription and non-prescription drugs,
human biologicals including vaccines, and immunologicals,
veterinary pharmaceuticals, including prescription and non-prescription drugs, with the exclusion of veterinary immunologicals,
pre-mixes for the preparation of veterinary medicated feeds (EC), Type A medicated articles for the preparation of veterinary medicated feeds (US),
intermediate products and active pharmaceutical ingredients or bulk pharmaceuticals (US)/starting materials (EC).
Appendix 4
Criteria for Assessing Equivalence for Post- and Pre-Approval
Legal/Regulatory authority and structures and procedures providing for post- and pre-approval:
A. Appropriate statutory mandate and jurisdiction.
B. Ability to issue and update binding requirements and GMPs and guidance documents.
C. Authority to make inspections, review and copy documents, and to take samples and collect other evidence.
D. Ability to enforce requirements and to remove products found in violation of such requirements from the market.
E. Substantive current good manufacturing requirements.
F. Accountability of the regulatory authority.
G. Inventory of current products and manufacturers.
H. System for maintaining or accessing inspection reports, samples and other analytical data, and other firm/product information relating to matters covered by this Sectoral Annex.
Mechanisms in place to assure appropriate professional standards and avoidance of conflicts of interest.
Administration of the regulatory authority:
A. Standards of education/qualification and training.
B. Effective quality assurance systems measures to ensure adequate job performance.
C. Appropriate staffing and resources to enforce laws and regulations.
Conduct of Inspections:
A. Adequate pre-inspection preparation, including appropriate expertise of investigator/team, review of firm/product and databases, and availability of appropriate inspection equipment.
B. Adequate conduct of inspection, including statutory access to facilities, effective response to refusals, depth and competence of evaluation of operations, systems and documentation; collection of evidence; appropriate duration of inspection and completeness of written report of observations to firm management.
C. Adequate post-inspection activities, including completeness of inspectors' report, inspection report review where appropriate, and conduct of follow-up inspections and other activities where appropriate, assurance of preservation and retrieval of records.
Execution of regulatory enforcement actions to achieve corrections, designed to prevent future violations, and to remove products found in violation of requirements from the market.
Effective Use of Surveillance Systems:
A. Sampling and analysis.
B. Recall monitoring.
C. Product defect reporting system.
D. Routine surveillance inspections.
E. Verification of approved manufacturing process changes to marketing authorisations/approved applications.
Additional specific criteria for pre-approval inspections
A. Satisfactory demonstration through a jointly developed and administered training program and joint inspections to assess the authorities' capabilities.
B. Pre-inspection preparation includes the review of appropriate records, including site plans and drug master file or similar documentation to enable adequate inspections.
C. Ability to verify chemistry, manufacturing and control data supporting an application is authentic and complete.
D. Ability to access and evaluate research and development data as scientifically sound, especially transfer technology of pilot, scale up and full scale production batches.
E. Ability to verify conformity of the on site processes and procedures with those described in the application.
F. Review and evaluate equipment installation, operational and performance qualification data, and evaluate test method validation.
Appendix 5
Elements to be Considered in Developing a Two-way Alert System
Documentation
Defintion of a crisis/emergency and under what circumstances an alert is required,
Standard Operating Procedures (SOPs),
Mechanism of health hazards evaluation and classification,
Language of communication and transmission of information.
Crisis Management System
Crisis analysis and communication mechanisms,
Establishment of contact points,
Reporting mechanisms.
Enforcement Procedures
Follow-up mechanisms,
Corrective action procedures.
Quality Assurance System
Pharmacovigilance programme,
Surveillance/monitoring of implementation of corrective action.
Contact points
For the purpose of this agreement, the contact points for the alert system will be:
for the European Community:
the Executive Director of the European Agency for the Evaluation of Medicinal Products,
7, Westferry Circus,
Canary Wharf
UK - London E14 4HB,
England.
Telephone +44- 171- 418 8400,
Fax 418 8416.
for the United States:
(to be provided by the U.S.)